Toxicity in Clinical Trials Trips Renal Cell Carcinoma Drugs

0
108

An FDA advisory committee deadlocked 6 to 6 on whether the benefits of a Pfizer drug treatment for recurrent renal cell carcinoma outweighed the risks. FDA representatives noted the drug was associated with more toxicities than the placebo in clinical trials.

Comments

comments